H.R. 5160

119 HR 5160 EH: Stem Cell Therapeutic and Research Reauthorization Act of 2025
 U.S. House of Representatives
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 IB
 119th CONGRESS  2d Session
 H. R. 5160
 IN THE HOUSE OF REPRESENTATIVES
 AN ACT
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
1.
Short title
This Act may be cited as the   Stem Cell Therapeutic and Research Reauthorization Act of 2025  .
2.
Reauthorization of the C.W. Bill Young Cell Transplantation Program
Section 379B of the Public Health Service Act ( 42 U.S.C. 274m ) is amended—
(1)
by striking  appropriated $31,009,000  and inserting the following:
appropriated—
(1)
$31,009,000
 ;
(2)
in paragraph (1), as so inserted, by striking the period at the end and inserting  ; and ; and
(3)
by adding at the end the following:
(2)
$33,009,000 for each of fiscal years 2027 through 2031.
 .
3.
Cord blood inventory
(a)
In general
Section 2(a) of the Stem Cell Therapeutic and Research Act of 2005 ( 42 U.S.C. 274k  note) is amended by striking  at least 150,000 new units of high-quality cord blood  and inserting  a sufficient supply, as determined by the Secretary, of high-quality cord blood units .
(b)
Application
Section 2(c) of such Act ( 42 U.S.C. 274k  note) is amended—
(1)
in paragraph (2), by striking  in perpetuity or ; and
(2)
by amending paragraph (5) to read as follows:
(5)
if the Secretary determines through an assessment, or through petition by the applicant, that a cord blood bank is no longer operational, does not meet the requirements described in subsection (d)(4), or does not meet the requirements of section 379(d)(4) of the Public Health Service Act, and as a result may not distribute the high-quality units, the Secretary may transfer the units collected pursuant to this section to another qualified cord blood bank or entity approved by the Secretary to ensure continued availability of high-quality cord blood units.
 .
(c)
Duration of Contracts
Section 2(d)(4) of such Act ( 42 U.S.C. 274k  note) is amended to read as follows:
(4)
Consideration of best science
The Secretary shall take into consideration current scientific and clinical information in order to maximize the availability of high-quality cord blood units meeting applicable clinical and quality standards for transplant when entering into contracts under this section, or when extending a period of funding under such a contract under paragraph (2).
 .
(d)
Inventory management
Section 2 of such Act ( 42 U.S.C. 274k  note) is amended—
(1)
by redesignating subsections (e), (f), and (g) and as subsections (f), (g), and (h), respectively; and
(2)
by inserting after subsection (d) the following:
(e)
Inventory management
(1)
In general
The Secretary shall manage the size and composition of the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote the efficient use of resources.
(2)
Considerations
In carrying out paragraph (1), the Secretary may—
(A)
on the Secretary’s own initiative or upon petition by a qualified cord blood bank, make determinations regarding the continued storage of cord blood units based on the best available scientific and clinical evidence; or
(B)
prioritize the collection, retention, or disposition of cord blood units based on scientific, clinical, or operational considerations that the Secretary determines to be relevant.
 .
(e)
Definitions
Section 2(g) of such Act, as redesignated by subsection (d)(1) of this section, is amended—
(1)
by redesignating paragraphs (4) and (5) as paragraphs (5) and (6), respectively; and
(2)
by inserting after paragraph (3) the following:
(4)
The term  high quality cord blood unit  means a cord blood unit that meets current industry standards and any requirements of the Food and Drug Administration.
 .
(f)
Authorization of appropriations
Section 2(h) of such Act, as redesignated by subsection (d)(1) of this section, is amended by striking  fiscal years 2022 through 2026  and inserting  fiscal years 2027 through 2031 .
     Passed the House of Representatives July 20, 2026.  Kevin F. McCumber,  Clerk.